Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.40 |
| ▸ | FABP6 | P51161 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067913 | 1.00 | KDR (0.46) | KDRHPGDPDGFRBFABP6LMNA | |
| SCHEMBL3457136 | 0.90 | MTHFD2 (0.41) | KDR | |
| SCHEMBL5072647 | 0.88 | KDR (0.49) | KDRHPGDPDGFRBLMNA | |
| SCHEMBL3457964 | 0.88 | KDR (0.49) | KDRHPGDPDGFRBLMNA | |
| SCHEMBL3455611 | 0.86 | GRM5 (0.43) | GUSB | |
| SCHEMBL3455647 | 0.85 | SMN1; SMN2 (0.43) | LMNAGUSB | |
| SCHEMBL3457113 | 0.82 | PIK3CA (0.38) | HPGDLMNACFTR | |
| SCHEMBL14031952 | 0.82 | HPSE (0.41) | HPGDLMNA | |
| SCHEMBL3456798 | 0.81 | ALDH1A1 (0.51) | HPGDLMNATDP1 | |
| SCHEMBL3456012 | 0.81 | P2RX7 (0.44) | HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251340-A1 | Substituted tetrahydro-1h-pyrazolo[3,4-c] pyridines, compositions containing same and use thereof | Aventis Pharma S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7109340-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2006-09-19 | — | — | US | disclosed |
| US-20060199837-A1 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE | AVENTIS PHARMA S.A. (FR) | 2006-09-07 | — | — | US | disclosed |
| EP-1646632-A2 | SUBSTITUTED TETRAHYDRO-1 I H /I -PYRAZOLO 3,4-C|PYRIDINES, COMPOSITIONS CONTAINING SAME AND USE | Aventis Pharma S.A. (FR) | 2006-04-19 | — | — | EP | disclosed |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2005-05-05 | — | — | US | disclosed |
| WO-2005007653-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINES, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199837-A1 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE | BRD4, TP53, HCCS | KDR 1415/4885HPGD 1060/4885PDGFRB 440/4885 |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | BRD4, TP53, HCCS | KDR 1542/4885HPGD 736/4885PDGFRB 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.